Hospital
Jersey City Medical Center
Jersey City Medical Center was paid $336.38M by Medicaid between Jan 2018 and Dec 2024, across 582 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
33Billing provider infoJERSEY CITY MEDICAL CENTER
JERSEY CITY, NJ 07302
JERSEY CITY, NJ 07302
33aNPI1689744856assigned 11/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$336.38M
24GClaims3,176,722
24DCodes billed582
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#3 of 93
Median peer was paid$30.60M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 412,871 | $47.57M | |
| 2019 | 430,069 | $50.40M | |
| 2020 | 332,854 | $35.13M | |
| 2021 | 429,380 | $44.41M | |
| 2022 | 499,360 | $44.26M | |
| 2023 | 573,060 | $56.40M | |
| 2024incomplete | 499,128 | $58.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 100,033 | 89,779 | $37.02M |
| G0378 | Hospital observation service, per hour | 9.5% | 39,941 | 31,067 | $32.08M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.5% | 79,293 | 70,245 | $31.87M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.9% | 56,159 | 49,239 | $30.05M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 8.8% | 99,120 | 75,341 | $29.65M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 6.2% | 77,767 | 7,206 | $21.01M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 3.7% | 27,763 | 24,062 | $12.45M |
| S9480 | Intensive outpatient psychiatric services, per diem | 2.3% | 10,266 | 8,226 | $7.77M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 28,613 | 26,271 | $7.38M |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | 1.7% | 7,522 | 6,681 | $5.72M |
| OP250 | 1.4% | 190,005 | 119,624 | $4.76M | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 2,957 | 2,806 | $4.54M |
570 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 5,264 | $3.67M |
| T2034 | Crisis intervention, waiver; per diem | 1.0% | 4,091 | $3.50M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 2,187 | $3.10M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 13,796 | $2.85M |
| 93017 | <1% | 5,311 | $2.47M | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 6,794 | $2.34M |
| OP370 | <1% | 19,558 | $2.14M | |
| OP710 | <1% | 21,313 | $2.07M | |
| A0425 | Ground mileage, per statute mile | <1% | 120,662 | $1.98M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 35,872 | $1.86M |
| 76818 | <1% | 9,613 | $1.85M | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 16,728 | $1.83M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 51,752 | $1.82M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 29,329 | $1.80M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 27,184 | $1.79M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 43,054 | $1.71M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 71,436 | $1.70M |
| 93458 | <1% | 922 | $1.69M | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,869 | $1.58M |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 30,761 | $1.53M |
| 93975 | <1% | 5,928 | $1.50M | |
| A0998 | Ambulance response and treatment, no transport | <1% | 10,100 | $1.42M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 17,222 | $1.41M |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 12,108 | $1.40M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,871 | $1.40M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 3,713 | $1.37M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 773 | $1.34M |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 25,386 | $1.33M |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 7,967 | $1.32M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 36,064 | $1.27M |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 17,221 | $1.26M |
| 97010 | <1% | 50,622 | $1.24M | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 2,147 | $1.21M |
| OP272 | <1% | 21,942 | $1.21M | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 42,382 | $1.20M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 51,624 | $1.18M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 30,851 | $1.13M |
| C1776 | Joint device (implantable) | <1% | 439 | $964K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 22,250 | $964K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,026 | $937K |
| 80053 | Comprehensive metabolic panel | <1% | 82,778 | $922K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 9,657 | $890K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 10,823 | $860K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 3,972 | $857K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 6,350 | $835K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 36,762 | $832K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 14,742 | $827K |
| 93970 | <1% | 3,113 | $803K | |
| 90837 | Psychotherapy session, about an hour | <1% | 10,623 | $798K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 27,304 | $765K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,066 | $734K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,206 | $706K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 96,375 | $696K |
| A0434 | Specialty care transport (sct) | <1% | 625 | $644K |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 878 | $642K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 388 | $637K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,063 | $607K |
| 76830 | Ultrasound, transvaginal | <1% | 6,097 | $576K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,961 | $572K |
| 71045 | Radiologic examination, chest; single view | <1% | 21,369 | $566K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 9,995 | $563K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,580 | $544K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 7,469 | $540K |
| OP278 | <1% | 905 | $539K | |
| 76801 | <1% | 7,351 | $529K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,231 | $502K |
| A0433 | Advanced life support, level 2 (als 2) | <1% | 1,029 | $468K |
| 70486 | <1% | 3,458 | $444K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 4,290 | $428K |
| 93971 | <1% | 3,372 | $404K | |
| 73564 | <1% | 7,759 | $402K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,036 | $379K |
| 73130 | <1% | 9,274 | $369K | |
| S9484 | Crisis intervention mental health services, per hour | <1% | 527 | $360K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 10,080 | $351K |
| OP258 | <1% | 64,140 | $343K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,596 | $340K |
| 76642 | <1% | 3,303 | $339K | |
| 76820 | <1% | 3,033 | $337K | |
| 84484 | <1% | 32,764 | $321K | |
| 73630 | <1% | 8,559 | $314K | |
| 73610 | <1% | 9,183 | $312K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,202 | $311K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,040 | $303K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,739 | $296K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,805 | $284K |
| 73110 | <1% | 7,378 | $282K | |
| 73030 | <1% | 6,459 | $281K | |
| 77066 | Tomosynthesis, mammo | <1% | 2,248 | $279K |
| 94060 | <1% | 1,089 | $272K | |
| 76813 | <1% | 2,322 | $263K | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 146 | $254K |
| 92579 | <1% | 865 | $252K | |
| 82948 | <1% | 19,773 | $239K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,181 | $236K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,562 | $226K |
| 92567 | <1% | 3,169 | $226K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 302 | $218K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 22,956 | $206K |
| 86850 | <1% | 14,557 | $205K | |
| 96376 | <1% | 7,570 | $200K | |
| 14301 | <1% | 152 | $196K | |
| 77412 | <1% | 317 | $192K | |
| 73590 | <1% | 5,300 | $190K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 40 | $188K |
| 77065 | Tomosynthesis, mammo | <1% | 2,135 | $187K |
| 73562 | <1% | 4,234 | $185K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,626 | $183K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,065 | $183K |
| 90785 | <1% | 3,577 | $183K | |
| 64483 | <1% | 112 | $181K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 4,332 | $181K |
| 97161 | <1% | 5,051 | $180K | |
| 97162 | <1% | 4,701 | $178K | |
| A9270 | Non-covered item or service | <1% | 48,234 | $177K |
| 20610 | <1% | 473 | $168K | |
| 70496 | <1% | 1,006 | $166K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,951 | $166K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,249 | $164K |
| 77080 | <1% | 1,938 | $162K | |
| 70498 | <1% | 1,025 | $161K | |
| 96415 | <1% | 943 | $161K | |
| 62323 | <1% | 116 | $160K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,885 | $159K |
| 73080 | <1% | 4,491 | $157K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 4,468 | $156K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 3,126 | $150K |
| 72110 | <1% | 2,518 | $149K | |
| 73090 | <1% | 4,125 | $146K | |
| 36430 | <1% | 753 | $145K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 4,640 | $144K |
| 70491 | <1% | 687 | $142K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 58,014 | $139K |
| 86900 | <1% | 14,900 | $136K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,907 | $131K |
| Q3014 | Telehealth originating site facility fee | <1% | 6,553 | $130K |
| 0223U | <1% | 1,293 | $127K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,868 | $126K |
| 96367 | <1% | 1,849 | $126K | |
| 86803 | <1% | 20,802 | $126K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 192 | $123K |
| 95811 | <1% | 41 | $122K | |
| 12001 | <1% | 1,535 | $120K | |
| 76641 | <1% | 630 | $119K | |
| 62322 | <1% | 80 | $118K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 504 | $118K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 8,466 | $115K |
| 74174 | <1% | 465 | $115K | |
| C1781 | Mesh (implantable) | <1% | 239 | $113K |
| 10060 | <1% | 752 | $112K | |
| 47562 | <1% | 71 | $112K | |
| 97166 | <1% | 2,657 | $112K | |
| 96417 | <1% | 575 | $104K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 7,205 | $103K |
| 72131 | <1% | 979 | $101K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 1,816 | $99K |
| 95800 | <1% | 163 | $99K | |
| 85730 | <1% | 24,000 | $95K | |
| 12011 | <1% | 1,231 | $95K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 3,368 | $94K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 11,467 | $91K |
| 81025 | <1% | 23,870 | $90K | |
| 73502 | <1% | 3,970 | $90K | |
| 86901 | <1% | 14,944 | $90K | |
| 94726 | <1% | 919 | $90K | |
| 85610 | <1% | 25,006 | $88K | |
| 82962 | <1% | 21,308 | $87K | |
| 92557 | <1% | 479 | $87K | |
| 27447 | <1% | 59 | $87K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 1,280 | $86K |
| 73060 | <1% | 2,515 | $85K | |
| 76536 | <1% | 688 | $84K | |
| 81001 | <1% | 26,880 | $82K | |
| 71250 | <1% | 595 | $82K | |
| 77336 | <1% | 742 | $82K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,606 | $82K |
| 83735 | <1% | 17,648 | $81K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,015 | $79K |
| 73552 | <1% | 2,832 | $78K | |
| 92587 | <1% | 481 | $76K | |
| 97014 | <1% | 2,895 | $75K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 346 | $74K |
| 83690 | <1% | 22,306 | $74K | |
| 85027 | <1% | 15,170 | $73K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,983 | $72K |
| 93356 | <1% | 312 | $71K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 704 | $67K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,306 | $67K |
| 94729 | <1% | 543 | $67K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 26,424 | $67K |
| 83880 | <1% | 6,693 | $67K | |
| 73140 | <1% | 2,421 | $66K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,307 | $66K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 5,242 | $62K |
| 97116 | <1% | 3,346 | $61K | |
| 58558 | <1% | 40 | $60K | |
| 77334 | <1% | 134 | $59K | |
| 88312 | <1% | 2,853 | $58K | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 2,707 | $58K |
| 80320 | <1% | 3,892 | $57K | |
| 81003 | <1% | 21,338 | $56K | |
| 88304 | <1% | 3,126 | $55K | |
| 97168 | <1% | 1,045 | $53K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,865 | $53K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 519 | $52K |
| 74018 | <1% | 1,869 | $51K | |
| 80061 | Lipid panel | <1% | 4,659 | $51K |
| OP379 | <1% | 458 | $50K | |
| 92523 | <1% | 642 | $49K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,239 | $47K |
| 29125 | <1% | 807 | $47K | |
| 87040 | <1% | 4,040 | $45K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,337 | $45K |
| 76870 | <1% | 813 | $44K | |
| G0269 | Placement of occlusive device into either a venous or arterial access site, post surgical or interventional procedure (e.g., angioseal plug, vascular plug) | <1% | 359 | $43K |
| 97165 | <1% | 880 | $43K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 3,079 | $43K |
| 73000 | <1% | 551 | $43K | |
| C1769 | Guide wire | <1% | 2,266 | $43K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,142 | $42K |
| 98971 | <1% | 1,667 | $41K | |
| 84702 | <1% | 5,720 | $40K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,001 | $38K |
| OP402 | <1% | 45 | $36K | |
| 95806 | <1% | 117 | $36K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,269 | $35K |
| OP637 | <1% | 8,972 | $35K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 736 | $35K |
| 82805 | <1% | 2,635 | $34K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,699 | $34K |
| 93976 | <1% | 670 | $34K | |
| 83605 | <1% | 3,983 | $34K | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,481 | $34K |
| 76821 | <1% | 229 | $33K | |
| 87428 | <1% | 431 | $33K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,662 | $33K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 599 | $30K |
| 72170 | <1% | 1,254 | $30K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,092 | $29K |
| 84100 | <1% | 4,944 | $29K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,112 | $29K |
| 12002 | <1% | 329 | $29K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 587 | $29K |
| 29705 | <1% | 310 | $29K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,212 | $27K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 466 | $26K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 781 | $26K |
| 44970 | <1% | 14 | $26K | |
| 76770 | <1% | 328 | $25K | |
| 73560 | <1% | 535 | $25K | |
| 87902 | <1% | 231 | $25K | |
| OP255 | <1% | 4,188 | $24K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,343 | $24K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,111 | $24K |
| 90715 | <1% | 2,522 | $24K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,306 | $23K |
| 72100 | <1% | 536 | $23K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,274 | $22K |
| OP270 | <1% | 2,130 | $22K | |
| 93880 | <1% | 109 | $22K | |
| 87631 | <1% | 539 | $22K | |
| 72050 | <1% | 342 | $22K | |
| 85007 | <1% | 6,205 | $21K | |
| 87340 | <1% | 5,448 | $21K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,798 | $21K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 218 | $20K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 40 | $20K |
| 97164 | <1% | 551 | $20K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,931 | $20K |
| 80076 | <1% | 2,356 | $20K | |
| 84550 | <1% | 479 | $20K | |
| 76775 | <1% | 248 | $20K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 648 | $19K |
| 88307 | <1% | 329 | $19K | |
| 87522 | Neg quan hep c or qual rna | <1% | 585 | $18K |
| 87430 | <1% | 2,884 | $18K | |
| 90750 | <1% | 178 | $18K | |
| 92553 | <1% | 265 | $17K | |
| 15853 | <1% | 329 | $17K | |
| 71101 | <1% | 370 | $17K | |
| 86920 | <1% | 449 | $16K | |
| 95819 | <1% | 25 | $16K | |
| 82375 | <1% | 2,535 | $16K | |
| 92083 | <1% | 607 | $16K | |
| 73700 | <1% | 142 | $15K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 46 | $15K |
| 49083 | <1% | 23 | $15K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 382 | $15K |
| 87400 | <1% | 3,456 | $15K | |
| 92133 | <1% | 929 | $15K | |
| 72128 | <1% | 103 | $15K | |
| 64484 | <1% | 51 | $14K | |
| 86140 | <1% | 4,620 | $13K | |
| 29075 | <1% | 88 | $13K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 208 | $13K |
| 0240U | <1% | 295 | $13K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,989 | $13K |
| 87081 | <1% | 3,571 | $13K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,505 | $13K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,417 | $12K |
| J7510 | Prednisolone oral, per 5 mg | <1% | 752 | $12K |
| 85378 | <1% | 3,277 | $12K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,777 | $11K |
| 77300 | <1% | 62 | $11K | |
| 20553 | <1% | 14 | $11K | |
| 87807 | <1% | 2,317 | $11K | |
| 97802 | <1% | 664 | $11K | |
| 93226 | <1% | 28 | $11K | |
| 95913 | <1% | 12 | $11K | |
| 94760 | <1% | 194 | $10K | |
| 82728 | <1% | 1,227 | $10K | |
| 83050 | <1% | 2,586 | $10K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,837 | $10K |
| 85380 | <1% | 1,111 | $10K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 72 | $10K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,978 | $10K |
| 99201 | <1% | 122 | $10K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,843 | $9K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 238 | $9K |
| 72020 | <1% | 392 | $9K | |
| 80164 | <1% | 334 | $9K | |
| 80047 | <1% | 3,077 | $8K | |
| 36591 | <1% | 157 | $8K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 287 | $8K |
| 93225 | <1% | 28 | $8K | |
| 92134 | <1% | 477 | $8K | |
| 82542 | <1% | 713 | $8K | |
| 82550 | <1% | 2,243 | $7K | |
| 87186 | <1% | 1,088 | $7K | |
| 71100 | <1% | 260 | $7K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,501 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,335 | $7K |
| M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency | <1% | 65 | $7K |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | <1% | 275 | $6K |
| 99422 | <1% | 448 | $6K | |
| 80051 | <1% | 1,979 | $6K | |
| 77290 | <1% | 12 | $6K | |
| 85651 | <1% | 2,247 | $6K | |
| 14302 | <1% | 97 | $6K | |
| 29130 | <1% | 211 | $6K | |
| 93925 | <1% | 30 | $6K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 84 | $6K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 473 | $6K |
| 87088 | <1% | 1,942 | $6K | |
| 90686 | <1% | 620 | $5K | |
| 90677 | <1% | 186 | $5K | |
| 83550 | <1% | 1,034 | $5K | |
| 86592 | <1% | 1,458 | $5K | |
| 98972 | <1% | 128 | $5K | |
| 88313 | <1% | 233 | $5K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 465 | $5K |
| 91200 | <1% | 25 | $5K | |
| 85055 | <1% | 260 | $5K | |
| 87070 | <1% | 777 | $5K | |
| 82607 | <1% | 863 | $5K | |
| 95886 | <1% | 12 | $5K | |
| 82731 | <1% | 111 | $5K | |
| 82746 | <1% | 716 | $5K | |
| 92555 | <1% | 77 | $5K | |
| 90651 | <1% | 25 | $5K | |
| 76882 | <1% | 48 | $5K | |
| 87205 | <1% | 965 | $5K | |
| 83615 | <1% | 1,115 | $4K | |
| 97163 | <1% | 120 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 348 | $4K |
| 0001A | <1% | 126 | $4K | |
| 85018 | <1% | 2,330 | $4K | |
| 0002A | <1% | 124 | $4K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 341 | $4K |
| 87077 | <1% | 715 | $4K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 397 | $4K |
| 87536 | <1% | 43 | $4K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 712 | $4K |
| 90662 | <1% | 133 | $4K | |
| 98970 | <1% | 365 | $4K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 719 | $4K |
| 82985 | <1% | 457 | $4K | |
| 83540 | <1% | 1,043 | $4K | |
| A0422 | Ambulance (als or bls) oxygen and oxygen supplies, life sustaining situation | <1% | 401 | $3K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 107 | $3K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 71 | $3K |
| 84134 | <1% | 623 | $3K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 54 | $3K |
| 96523 | <1% | 46 | $3K | |
| 72141 | <1% | 13 | $3K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 271 | $3K |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 1,801 | $3K |
| 93923 | <1% | 16 | $3K | |
| 88341 | <1% | 45 | $3K | |
| 88342 | <1% | 162 | $3K | |
| 84156 | <1% | 614 | $3K | |
| 84439 | <1% | 483 | $3K | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 25 | $3K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 33 | $3K |
| 73523 | <1% | 40 | $3K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 386 | $3K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,097 | $3K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 484 | $2K |
| 72040 | <1% | 36 | $2K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 27 | $2K |
| 82947 | <1% | 517 | $2K | |
| 82248 | <1% | 881 | $2K | |
| 92610 | <1% | 12 | $2K | |
| 85652 | <1% | 1,108 | $2K | |
| 82330 | <1% | 391 | $2K | |
| 82652 | <1% | 104 | $2K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 53 | $2K |
| 87486 | <1% | 154 | $2K | |
| 84520 | <1% | 466 | $2K | |
| 87150 | <1% | 256 | $2K | |
| 70544 | <1% | 14 | $2K | |
| 87581 | <1% | 154 | $2K | |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 215 | $2K |
| 73522 | <1% | 30 | $2K | |
| 82378 | <1% | 159 | $2K | |
| 59025 | Fetal non-stress test | <1% | 13 | $2K |
| 0004A | <1% | 59 | $2K | |
| 90836 | <1% | 29 | $2K | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 357 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,285 | $2K |
| 99421 | <1% | 255 | $2K | |
| T1017 | Case management, billed per 15 minutes | <1% | 17 | $2K |
| OP510 | <1% | 37 | $2K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 197 | $2K |
| 82150 | <1% | 228 | $2K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 29 | $2K |
| A4648 | Tissue marker, implantable, any type, each | <1% | 52 | $2K |
| 82803 | <1% | 105 | $2K | |
| 82570 | <1% | 496 | $2K | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 135 | $2K |
| 94660 | <1% | 50 | $1K | |
| 93922 | <1% | 24 | $1K | |
| 92225 | <1% | 28 | $1K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 373 | $1K |
| 84703 | <1% | 494 | $1K | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 41 | $1K |
| 80329 | <1% | 110 | $1K | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 134 | $1K |
| 96368 | <1% | 38 | $1K | |
| 87075 | <1% | 214 | $1K | |
| 87147 | <1% | 304 | $1K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 32 | $1K |
| 82784 | <1% | 48 | $1K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 616 | $1K |
| 93990 | <1% | 14 | $1K | |
| 80074 | <1% | 79 | $1K | |
| 92526 | <1% | 28 | $1K | |
| 0054A | <1% | 35 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 63 | $1K |
| 90674 | <1% | 167 | $994.45 | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 26 | $993.63 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,124 | $986.25 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,093 | $934.18 |
| 73200 | <1% | 12 | $912.63 | |
| 0064A | <1% | 27 | $896.91 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 574 | $861.72 |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 86 | $861.50 |
| 97032 | <1% | 27 | $855.65 | |
| 80143 | <1% | 182 | $837.07 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 755 | $831.51 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,361 | $805.20 |
| 85384 | <1% | 146 | $791.18 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 49 | $790.24 |
| 0031A | <1% | 62 | $789.40 | |
| 86308 | <1% | 220 | $765.12 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 392 | $723.23 |
| 80179 | <1% | 114 | $684.98 | |
| 36600 | <1% | 71 | $677.91 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 478 | $652.45 |
| 73070 | <1% | 46 | $609.34 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 27 | $601.02 |
| 86359 | <1% | 15 | $590.00 | |
| 90656 | <1% | 70 | $586.89 | |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 124 | $569.27 |
| 74022 | <1% | 32 | $534.06 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 373 | $523.71 |
| 86703 | <1% | 36 | $497.60 | |
| 0071A | <1% | 12 | $485.60 | |
| 84145 | <1% | 40 | $482.52 | |
| 86780 | <1% | 61 | $470.80 | |
| 86923 | <1% | 61 | $455.64 | |
| 72070 | <1% | 12 | $453.14 | |
| 86334 | <1% | 28 | $438.10 | |
| 86300 | <1% | 35 | $436.97 | |
| 92020 | <1% | 12 | $436.90 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 372 | $432.91 |
| 73660 | <1% | 40 | $402.29 | |
| 93463 | <1% | 13 | $345.58 | |
| 29505 | <1% | 15 | $342.21 | |
| 88311 | <1% | 26 | $325.17 | |
| 85045 | <1% | 231 | $324.32 | |
| 92060 | <1% | 15 | $315.00 | |
| C7900 | Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 15-29 minutes, provided remotely by hospital staff who are licensed to provide mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service | <1% | 462 | $300.05 |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 187 | $274.38 |
| 90671 | <1% | 16 | $253.20 | |
| 85044 | <1% | 191 | $249.45 | |
| 86706 | <1% | 49 | $245.13 | |
| 86038 | <1% | 47 | $240.30 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 30 | $230.32 |
| 87641 | <1% | 45 | $225.21 | |
| 84165 | <1% | 49 | $207.67 | |
| J7605 | Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms | <1% | 33 | $201.64 |
| 86160 | <1% | 15 | $196.38 | |
| 86200 | <1% | 15 | $194.34 | |
| 80185 | <1% | 15 | $192.40 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 81 | $189.40 |
| 90697 | <1% | 171 | $178.59 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 385 | $171.30 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 223 | $168.96 |
| 92002 | <1% | 12 | $167.51 | |
| D0330 | Panoramic radiographic image | <1% | 66 | $155.71 |
| 88112 | <1% | 15 | $147.16 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 157 | $136.40 |
| 81002 | <1% | 40 | $135.38 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 91 | $124.96 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 39 | $123.32 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 26 | $122.32 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 192 | $117.43 |
| 90680 | <1% | 170 | $108.79 | |
| 90688 | <1% | 12 | $107.28 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 46 | $105.40 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 47 | $104.32 |
| 85347 | <1% | 13 | $103.24 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 475 | $102.86 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 78 | $97.32 |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 54 | $97.13 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 437 | $94.60 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 213 | $91.03 |
| 80177 | <1% | 25 | $90.30 | |
| 82565 | <1% | 35 | $71.71 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 13 | $70.99 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 167 | $70.76 |
| 83010 | <1% | 15 | $70.48 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 26 | $59.49 |
| J3490 | Unclassified drugs | <1% | 13 | $58.09 |
| 84300 | <1% | 25 | $54.49 | |
| 90673 | <1% | 14 | $49.94 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 51 | $47.36 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 171 | $46.71 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 61 | $46.11 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 82 | $45.91 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 842 | $37.96 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 38 | $37.26 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 87 | $35.44 |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | <1% | 400 | $34.27 |
| G2062 | Qualified nonphysician healthcare professional online assessment and management service, for an established patient, for up to seven days, cumulative time during the 7 days; 11-20 minutes | <1% | 17 | $33.02 |
| 86880 | <1% | 14 | $31.20 | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 25 | $30.00 |
| D0140 | Limited oral evaluation - problem focused | <1% | 76 | $28.20 |
| 88300 | <1% | 12 | $27.52 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 46 | $26.58 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 23 | $15.67 |
| 91300 | <1% | 263 | $13.81 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 12 | $11.77 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 16 | $10.64 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 19 | $9.91 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 20 | $7.00 |
| 91303 | <1% | 40 | $7.00 | |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | <1% | 17 | $6.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 15 | $5.79 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 15 | $5.00 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 417 | $4.93 |
| 85014 | <1% | 13 | $4.61 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 12 | $3.00 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | <1% | 14 | $2.00 |
| J2372 | Injection, phenylephrine hydrochloride (biorphen), 20 micrograms | <1% | 45 | $1.00 |
| 91307 | <1% | 12 | $1.00 | |
| 82810 | 0% | 15 | $0.00 | |
| 88160 | 0% | 15 | $0.00 | |
| 99080 | 0% | 79 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKYRIACOU, JONATHAN (CEO)
Parent organizationRWJ BARNABAS HEALTH INC
| Provider | Location | Paid |
|---|---|---|
| Jersey City Medical Center | Jersey City, NJ | $423K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.